Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 31, 2002

Study Completion Date

July 31, 2005

Conditions
Major Depression
Interventions
DRUG

Selegiline Transdermal System

Trial Locations (15)

21201

Mitchel Kling, M.D., Baltimore

30308

Robert Riesenberg, M.D., Atlanta

32789

Andrew Cutler, M.D., Winter Park

33154

Barry Baumel, M.D., Miami Beach

33321

Larry Eisner, M.D., Tamarack

33437

Abbey Strauss, M.D., Boynton Beach

33702

Margarita Nunez, M.D., St. Petersburg

33710

Mildred Farmer, M.D., St. Petersburg

41042

James Hartford, M.D., Florence

73103

Louise Beckett, M.D., Oklahoma City

76309

Penny Barnhart, M.D., Wichita Falls

91910

Mohammed Bari, M.D., Chula Vista

92108

Charles Meredith, M.D., San Diego

94589

Daniel Zimbroff, M.D., Upland

Kathleen Toups, M.D., Walnut Creek

Sponsors
All Listed Sponsors
lead

Somerset Pharmaceuticals

INDUSTRY